Here are the Form 4 insider transactions from Cerenome, Inc. (CNSY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CNSY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNSY filings page.
Cerenome, Inc. (CNSY) director An van Es-Johansson vested 921 restricted stock units on October 1, 2026, and acquired 921 shares of common stock. The RSU grant vests in four substantially equal quarterly installments beginning July 1, 2026. An van Es-Johansson held 1,843 common shares directly following the transaction.
Richard J. Hawkins, a director of Cerenome, Inc. (CNSY), had 921 restricted stock units vest on October 1, 2026, and acquired 921 shares of common stock. His reported holdings after the transaction were 2,450 common shares and 1,843 restricted stock units. The RSU grant vests in four substantially equal quarterly installments beginning July 1, 2026.
Cerenome, Inc. Chief Financial Officer Andrew John Hugh MacIntyre Sims reported three restricted stock unit grants vesting on October 1, 2026, and acquisition of 2,985 common shares. The three tranches were 1,533, 1,165 and 287 shares. Each Restricted Stock Unit represents a contingent right to receive one common share. No Rule 10b5-1 plan is reported.
Cerenome, Inc. (CNSY) reported vesting of 921 restricted stock units for director Howard Clowes on October 1, 2026, with 921 common shares acquired. Following the transactions, Howard Clowes directly held 2,902 common shares and 1,843 RSUs. The RSU grant vests in four substantially equal quarterly installments beginning July 1, 2026.
Cerenome, Inc. CEO and director Marc H. Hedrick reported vesting of three restricted stock unit grants on October 1, 2026, and acquired 6,387, 8,066 and 1,986 shares of common stock, respectively. The grants vest in 12 substantially equal quarterly installments, with schedules beginning on October 1, 2025, April 1, 2026 and July 1, 2026, respectively.
Cerenome, Inc. director Ronald Asbury Andrews reported vesting of 921 Restricted Stock Units on October 1, 2026; each unit represents a contingent right to receive one common share. The transaction also records acquisition of 921 common shares, with reported direct common-stock holdings of 1,843 shares afterward. The grant vests in four substantially equal quarterly installments beginning July 1, 2026.
Cerenome, Inc. (CNSY) director Kyle Guse reported vesting 921 restricted stock units on October 1, 2026, with 921 common shares acquired. Each RSU represents a contingent right to one common share. His reported direct common-stock position following the transaction was 1,843 shares. The grant vests in four substantially equal quarterly installments beginning July 1, 2026.